Furthermore, the nomogram consisting of GNAO1 expression and the TNM model presents good ability in predicting the 3-year relapse, suggesting that it could be a reliable biomarker of relapse prediction as well as a promising therapeutic target for HCC. The gene discussed is GNAO1; the disease is hepatocellular carcinoma.